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Abstract
Background: Adoptive T cell immunotherapy (ATCT) for cancer entails infusing patients with T cells that recognise
and destroy tumour cells. Efficient engraftment of T cells and persistence in the circulation correlate with favourable
clinical outcomes. T cells of early differentiation possess an increased capacity for proliferation and therefore
persistence, using these cells for ATCT could therefore lead to improved clinical outcomes.
Method: We describe a method to enrich T cells of early differentiation status using paramagnetic beads and
antibodies targeting cells expressing C-C motif chemokine receptor 7 (CCR7).
Results: Selection of cells expressing CCR7 enriches T cells of bearing markers of early differentiation status.
This was validated through analysis of an array of surface markers and an observed reduction in effector cell
functions ex vivo. CCR7 selection resulted in dramatic 83.6 and 137 fold increases in circulating levels of CD4
and CD8 T cells respectively compared to non-sorted T cells 3 weeks after adoptive transfer to NSG mice. We
observed no significant difference in the engraftment levels of CCR7 or CD62L selected cells in the NSG mouse model.
Comparison of cells ex vivo, however, suggests CCR7 selection is superior to CD62L selection in enriching T cells of
early differentiation status.
Conclusions: CCR7 selection offers a means to enrich T cells of early differentiation status for ACTC. Together our data
suggests that these T cells are likely to display enhanced engraftment and persistence in patients in vivo and could
therefore improve therapeutic efficacy of ACTC.
Keywords: CCR7, CD62L, Adoptive cell therapy, Immunotherapy, Differentiation status, Transgenic TCR, Central
memory, DMF5
Background
Adoptive T cell therapy (ATCT) using T cells armed with
recombinant T Cell Receptor (TCR) and Chimeric Anti-
gen Receptor (CAR) technologies is showing highly en-
couraging activity in early phase clinical testing against
several malignancies across a number of Institutions [1].
An emerging theme is that efficient engraftment and
long-term persistence of the therapeutic T cells correlates
with positive therapeutic outcomes. Several pre-clinical
studies have shown that naïve and early-differentiated T
cells possess an enhanced capacity for long term persist-
ence [2–4] and can elicit potent anti-tumour responses
[5–8]. Additionally, the increased persistence of adoptively
transferred cells appears to be dependent upon the acqui-
sition of central memory T cell (TCM) populations [9–12].
Stable gene transfer has been routinely achieved in the
clinical setting through the use of gamma retroviral vec-
tors to transduce polyclonal T cells with CARs [13–18]
and TCRs [19–21] with these engineered cells showing
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no obvious adverse safety indications in patients
engrafted with CAR T cells for greater than 10 years
[22]. For efficient transduction with retroviral vectors,
primary T cells need to be actively proliferating [23]
which is generally achieved through the mitogenic
stimulation of resting primary T cells by activation of the
TCR/CD3 complex to deliver ‘signal 1’ and through co-
stimulatory pathways such as CD28 to provide ‘signal 2’.
Lentiviral vectors are now commonly used in place of
gamma-retrovirus vectors for CAR and TCR gene ex-
pression although primary T cells still require mitogenic
activation for efficient transduction with standard lenti-
viral vectors used for research and clinical work [24, 25].
Upon activation, T cells progress in an irreversible linear
fashion towards an effector (TE) phenotype [26, 27]. Mito-
genic activation for retroviral or lentiviral transduction,
therefore, drives differentiation of T cells from a naïve to-
wards a TE phenotype [28]. In combination with ex-vivo
culture protocols to expand transduced T cell numbers to
those required for clinical application (~109–1011), T cells
are driven towards a more differentiated phenotype which
is sub-optimal for systemic persistence.
With this in mind, the concept of isolating naïve or
TCM as a source for gene-modified T cells to reduce the
extent of differentiation has been promoted with proto-
cols described using paramagnetic beads to enrich
CD62L+ (L-selectin) CD8+ T cells for transduction with
a recombinant TCR [29]. CD62L expression charac-
terises populations of T cells that possess lymphoid
homing capability and is routinely used to identify naïve
and effector memory T cells (TEM). However, CD62L ex-
pression on leukocytes is highly susceptible to freeze-
thaw damage [30] and there is the suggestion that
CD62L expression on CD4+ T cells is associated with a
Th2 cytokine profile rather than preferred Th1 profile for
cancer immunotherapy [31].
Similarly, expression of C-C motif chemokine receptor
7 (CCR7) identifies T cells that possess secondary
lymphoid tissue homing capacity and TCM characteris-
tics (CCR7+) as compared to CCR7− cells that possess
effector function and the capability to migrate into in-
flamed tissue [26, 32]. We hypothesised that CCR7+ T
cells may be optimal for adoptive T cell therapy. In this
work, we report that CCR7+ T cells transduced with a
TCR specific for a HLA-A*0201 restricted MART-1 epi-
tope maintain many features associated with reduced
differentiation and display enhanced engraftment in the
NSG mouse model.
Methods
T cell subset isolation
Blood was collected from healthy donors or buffy coats
(NHS Blood and Transplant Unit, Manchester, UK) and
peripheral blood mononuclear cells (PBMC) isolated by
Ficoll density centrifugation using Lymphocyte Separation
Medium (PAA Laboratories GmbH, Austria). CD3+ T cells
were enriched from PBMC by negative selection using a
Pan T cell Isolation kit (Miltenyi Biotec, Bergisch-
Gladbach, Germany). T cell subsets were labelled using
monoclonal antibodies to enable positive selection of the
relevant T cell populations. CCR7+ and CD62L+ T cells
were isolated from enriched CD3+ T cell fractions using
clones FR11-11E8 (Miltenyi Biotec, Germany) and DREG-
56 (eBioscence, USA) respectively; both of which were
conjugated to APC fluorophore. MACS separation based
on APC (Miltenyi Biotec, Germany) was used to isolate
CCR7+ or CD62L+ cells with negative fractions were col-
lected as effluent. Weakly positive CCR7+ T cells were re-
moved by passing cells from the CCR7− fraction over a
depletion column to allow residual CCR7+ cells to bind to
the magnetic column. Where sorting was performed after
cell culture, CD4+ T cells were depleted by positive selec-
tion (αCD4 antibody (RPA-T4-FITC, BD Bioscience, UK)
and anti-FITC microbeads) using MACS depletion col-
umns. Unlabelled CD8+ T cells were then labelled with
αCCR7-APC or αCD62L-APC antibodies for before separ-
ation as described above.
T cell activation
Non-selected, polyclonal T cell populations were acti-
vated by adding 30 ng/ml αCD3 (Orthoclone OKT3,
OrthoBiotech, UK) and αCD28 (37407.111, R&D sys-
tems, UK) to 106/mL PBMC in T cell media (RPMI 1640
media supplemented with 2 mM L-glutamine, 50 μM 2-
mercaptoethanol, 10% foetal calf serum and 100 IU/mL
Interluekin-2 (Chiron, The Netherlands). T cells which
had been through a prior CD3+ enrichment process
were activated, unless otherwise indicated, using human
αCD3/αCD28 Dynabeads (Life Technologies, Norway) at
concentration of 1 × 106 T cells/ml in T cell media and a
bead to T cell ratio of 1:1. MACSibeads (Miltenyi Biotec,
Germany) were prepared by incubation of 10 μg/ml of
each antibody (αCD2/αCD3/αCD28) with 108 beads.
Antibody-coated MACSibeads were then added to T
cells (106 T cells/mL) with a bead to T cell ratio of 1:2.
Irradiated PBMC feeder cells were generated by expos-
ing PBMCs from three separate donors to 30 Gy irradi-
ation before the addition of αCD3 and αCD28 antibodies,
both at 0.5 μg/ml. Irradiated allogeneic feeder cells were
added to cultures at a ratio of 2:1 T cells. K562 artificial
antigen presenting cells (aAPC, a kind gift from Dr Carl
June, University of Pennsylvania, USA) were exposed to
30 Gy irradiation and incubated with αCD3 and αCD28
antibodies (each at 0.5 μg/ml final concentration) prior to
addition to T cell cultures at a ratio of 2:1 T cells. Activa-
tion using plate bound antibodies was carried out by coat-
ing αCD3 and αCD28 antibodies on non-tissue culture
treated plates at a concentration of 1 μg/ml. Plates were
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washed and blocked with T cell media prior to the
addition of T cells at 1 × 106 cells/ml.
T cell transduction
RetroDMF5 encoding the α and β chains of the MART-1
specific DMF5 TCR receptor was obtained from a stably
transfected PG13 producer cell line. Viral supernatant was
collected and passed through a 0.45 μm filter (Appleton
Woods, UK) before immediate use or long-term storage
at −80 °C. Transductions were carried out by spinfection
using non-tissue culture 6 well plates coated in 10 μg/ml
RetroNectin (Takara Bio, Japan). Briefly, activated T cells
and virus were incubated overnight and the transduction
procedure repeated the following day. Where T -cells were
activated with magnetic beads, these were removed 4 h
following the second spinfection. T cells were then seeded
at a density of 5 × 105/ml in T cell media with cytokines as
indicated.
Flow cytometry
Relative frequency of expression of specific markers were
analysed using antibodies specific for αCD3, αCD8,
αCD45RA, αCD27, αCD28, αCCR7 (BD Biosciences)
and αCD62L (eBiosciences, USA). Where PBMCs ana-
lysed, Fc receptor block was used (Miltenyi Biotec,
Germany). To detect DMF5 TCR expression, a MART-
1/HLA*0201 antigen specific pentamer was used.
Ex vivo functionality assays
RetroDMF5 transduced T cells were analysed simultan-
eously for both surface antigen expression and intracellu-
lar production of multiple cytokines via flow cytometry.
Briefly, T cells were co-cultured with Mel-624 or Mel-888
cells at a ratio of 1:1 in the presence of 1 μl/ml GolgiPlug
(BD Bioscience, UK) for 16 h at 37 °C. T cells were sepa-
rated from from melanoma cell lines by a wash in 0.5 mM
EDTA, then a second wash in FACS buffer. T cells were
then stained for surface and intracellular antigens. T cell
polyfunctionality was determined using SPICE v5.3
software (Simplified Presentation of Incredibly Complex
Evaluations, distributed freely by National Institute of
Allergy and Infectious Diseases, NIH).
The cytotoxic potential of DMF5 TCR transduced T
cells was approximated by determining cell surface ex-
pression of CD107a following antigen specific T cell acti-
vation. Briefly, RetroDMF5 or mock transduced T cells
were incubated with Mel-624 or Mel-888 at a ratio of 1:1
in T cell media with 1.2 μl/ml GolgiStop (BD Biosciences,
UK). For analysis of CD107a expression, αCD107a-PE
antibody (BD Biosciences) was added and cells incubated
at 37 °C for 4 h, following which cells were washed,
stained with αCD8-FITC (BD Biosciences) and analysed
by flow cytometry. For analysis of IFNγ production, cells
were incubated at 37 °C for 16 h prior to intracellular flow
cytometry analysis.
In vivo experiments
Human T cells were injected intravenously into NSG im-
munodeficient mice (Harlan, UK). Blood samples were
collected by tail vein bleeds. All experiments were con-
ducted under the auspices of the Animals (Scientific
Procedures) Act 1986 and under U.K. Coordinating
Committee for Cancer Research guidelines.
Statistical analysis
Statistical analysis was performed using one-way or
two way ANOVA as required with Bonferonni’s post-
test. * P < 0.05, **P < 0.01, *** P < 0.001.
Results
CCR7 selection successfully enrich less differentiated
T cells
The chemokine receptor CCR7 is expressed on naïve,
stem cell memory (TSCM) and central memory (TCM) T
cells [27]. We developed an antibody-based paramag-
netic bead isolation approach to enrich CCR7+ T cells
from PBMCs to enrich for these early-differentiated T
cell subsets. The process involves enriching CD3+ T cells
from PBMCs by paramagnetic bead-based negative se-
lection then a further two-stage bead based isolation
strategy employing an initial staining of T cells with an
APC-conjugated anti-CCR7 antibody, followed by incu-
bation with anti-APC paramagnetic microbeads and
magnetic separation. Flow cytometry of positive and
negative fractions of cells confirms the ability of this
process to enrich for T cells expressing CCR7 (Fig. 1a).
Despite the wide variability in the relative proportion of
CCR7+ cells within the CD3+ T cell population of
healthy donors (mean: 36.2% SD ± 14.6%, range: 16.9–
64.5%), CCR7+ T cells were routinely enriched about 2
fold to to 73.1% (SD ± 12.3%) while the negative fraction
was depleted about 14 fold to a level of 2.5% (SD ± 2.3%)
CCR7+ T cells (Fig. 1b).
The frequency of CD4+ T cells in CCR7+ selected cell
populations was 76.7% (SD ± 4.13%), significantly higher
than 69.0% (SD ± 2.68%) in non-selected T cells (NSCs;
P < 0.05) and 65.2% (SD ± 8.48%) present in CCR7− cell
fractions (P < 0.01; Fig. 1c). Rises in CD4+ T cell fre-
quency were concomitant with a reduction in CD8+ T
cell frequency (Additional file 1A). CCR7 expression has
been identified in certain subsets of regulatory T cells
(Tregs) [33], which, if enriched, could inhibit effector
functions of adoptively transferred T cells in vivo. How-
ever, there was no increase in the relative frequency of
CD25+ CD127− FoxP3+ Tregs within the CCR7+ T cell
population. Unexpectedly, there was a 4.2 fold increase
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in Tregs in the CCR7− population as compared to NSCs
(P < 0.01; Fig. 1d).
Based upon reported determinants of T cell differenti-
ation status [27, 34], CCR7 selection enriched naïve
(CCR7+ CD45RA+) T cells in both CD4+ and CD8+ com-
partments (2.2 and 2.7 fold respectively) and caused a
reduction in both effector memory (TEM, CCR7
−
CD45RA−) (4.4 and 6.1 fold respectively) and effector (TE,
TEMRA/effector, CCR7
− CD45RA+) T cells (1.7 and 3.0 fold
respectively) when compared to NSCs. Conversely, a re-
duction in the proportion of naïve and an increase in TEM
in CD4+ and CD8+ subsets within the CCR7− population
Fig. 1 Early differentiated T cell selection using CCR7. a Representative plot following Isolation of early differentiated T cells using immuno-magnetic
beads against CCR7. A1 CCR7+ and A2 CCR7− fractions. The frequency of b CCR7+, c CD4+ and d CD25+ CD127− FoxP3+ Tregs in each fraction following
CCR7 selection as determined by flow cytometry. NSC Non sorted control T cells. Error bars ± SD, statistical tests one way ANOVAs with Bonferroni’s
post-test. e and f The phenotype of CD8+ and CD4+ T cell populations respectively following CCR7 selection; Naïve (CCR7+ CD45RA+), Central memory
(CCR7+ CD45RA−), Effector memory (CCR7− CD45RA−), Effector (CCR7− CD45RA+). Error bars show± SEM. For each phenotype; significant difference from
NSC T cells is shown. * P< 0.05, **P< 0.01, *** P < 0.001
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was observed (Fig. 1e and f ). A trend of increased rela-
tive expression of both CD27 and CD62Lhi in CCR7+
populations was not statistically significant relative to
NSCs. Simultaneous decreases within CCR7− popula-
tions, however, were indeed. Relative proportions of
CD28 expressing cells were unchanged regardless of
CCR7 expression (Additional file 1B and C). Together,
these data show that selection based on CCR7 enriches
for T cells bearing an early-differentiated marker pheno-
type without co-enriching Tregs.
The context of mitogenic stimulation influences the
proliferation kinetics and phenotypic profile of
non-selected and CCR7+ T cells
Optimal retroviral transduction of human T cells occurs
48 h after mitogenic stimulation [35]. To analyse whether
the context of anti-CD3ε and anti-CD28 (αCD3/αCD28)
mitogenic antibodies had a differential impact upon T cell
subset proliferation, NSC, CCR7+ and CCR7− cell popula-
tions were stimulated with antibodies in different con-
texts: plate bound αCD3/αCD28, microbead bound
αCD3/αCD28 (dynabeads), cell sized microbead bound
αCD2/αCD3/αCD28 (MACSiBeads) and presentation of
αCD3/αCD28 by irradiated PBMCs (iPBMCs) and irradi-
ated K562 aAPC (iK562). A clear difference in the ability
of these divergent platforms to induce the short-term pro-
liferation of NSC, CCR7+ or CCR7− CD8+ T cell frac-
tions was found. Both dynabeads and MACSiBeads
induced a rapid burst of proliferation in CCR7+ and
NSC T cells above that observed with plate-bound or
cell based antibody presentation (Fig. 2a). CCR7− cells
displayed much lower proliferative capacity, character-
istic of a more differentiated phenotype, although
iK562 cells induced the highest proliferation of CCR7−
cells over 72 h (Fig. 2a). Despite these differences in
short-term proliferation, no significant difference in
transduction efficiency with dynabeads or MACsiBeads
platforms was observed (Additional file 2A).
Following transduction and IL-2 driven ex vivo culture
for 14 days, iK562 cells induced significantly greater ex-
pansion of NSCs than all other antibody activation
methods whilst dynabeads induced significantly greater
proliferation than iPBMCs (Fig. 2b). Dynabead activation
was also associated with the lowest relative proportion of
TE and also yielded the highest proportions of TCM within
the NSC population (Fig. 2c). Moreover, there were sig-
nificantly higher numbers of CD27+ cells upon activation
of NSCs with dynabeads and MACSiBeads, compared
with plate bound antibodies or iPBMCs (Fig. 2d). Dyna-
beads also maintained the highest frequency of CD62Lhi T
cells as compared to all other platforms (Fig. 2d).
In the case of CCR7+ selected cells, iK562 cells in-
duced significantly greater expansion than MACSiBeads,
iPBMCs and plate bound antibodies (P < 0.001) whilst
dynabeads induced significantly greater proliferation than
iPBMCs. Importantly, there was no significant difference
in the expansion of CCR7+ selected cells over 14 days in
the presence of iK562 cells and dynabeads (Fig. 2b). The
relative proportion of TCM was greater than all equivalent
conditions compared to NSCs. Moreover, the frequency of
TE cells was significantly decreased in dynabead, activated
cells compared to CCR7+ cells activated with plate bound
antibody (3.78 fold) or iPBMCs (3.37 fold) and the propor-
tion of TCM significantly increased compared to iK562 ac-
tivation (2.21 fold; Fig. 2c).
In CCR7− selected T cells, iK562 cells induced signifi-
cantly greater expansion than all other platforms
(Fig. 2b). Within the CCR7− derived populations, there
was no significant effect of mitogenic stimulation on dif-
ferentiation, with all of the populations consisting of
equivalent numbers of effector memory and effector
cells (Fig. 2c) with the only significant difference in sur-
face marker expression being a small but significant in-
crease in CD62Lhi+ cells between MACSiBead and
iPBMC activated cells (P < 0.05).
To summarise, short term proliferation was maximal
in cells activated with dynabeads and MACSiBeads, with
maximal 14-day expansion of CCR7+ T cells achieved
with dynabeads and iK562 cell αCD3/αCD28 antibody
activation. There was little variation in TEM populations
regardless of CCR7 selection or mitogen used. This
could be an artefact derived from T cell activation itself,
retrovirus transduction or cell culture conditions; alter-
natively, it may be reflective of normal T cell subsets.
However, these phenotype data show that activation of
unselected CD8+ T cells or CD8+ CCR7+ T cells with
dynabeads is superior to other mitogenic platforms
assessed at expanding T cells whilst retaining expression
of markers associated with early-differentiation status, in
particular yielding higher proportions of TCM and limiting
differentiation to TE.
CCR7+ selection yields younger T cells than CD62L+
selection
Having validated the ability of CCR7 selection to enrich
for minimally differentiated T cells and identifying dyna-
beads as an ideal mitogen to retain maximal levels of
TCM cells upon cell expansion, we compared this to an
analogous method being developed to enrich for early-
differentiated T cells for, selection based on CD62L ex-
pression [36–38].
Firstly we investigated whether selection based on
CD62L expression could enrich for T cells of early-
differentiation status. As with CCR7 selection, APC con-
jugated αCD62L and αAPC beads were used to separate
cells. In contrast to work elsewhere, upon phenotypic
analysis of separated cells there was no significant in-
crease in proportion of Naïve or TCM, nor decrease in
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Fig. 2 (See legend on next page.)
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TE following CD62L selection in either CD8
+ or CD4+ T
cells compared to NSCs (Fig. 3a and b). Conversely,
CD62L− cells contained enlarged proportions of TEM in
both CD8+ and CD4+ subpopulations (P < 0.001 in each
case) and a concomitant decrease in both naïve (P < 0.01
and P < 0.001 respectively) and TE (P < 0.05 and P < 0.001
respectively) (Fig. 3a and b).
Selecting immature cells at the start of cell culture of-
fers the advantage that cytokines and growth factors and
nutrients are only consumed by cells of desired pheno-
type and unwanted cells are discarded immediately.
However, despite enriching for less-differentiated cells
prior to cell culture we consistently observed significant
differentiation upon T cell expansion. We therefore in-
vestigated whether selection after expansion of NSCs
was superior for acquiring minimally differentiated T
cells compared to CCR7 selection prior to expansion.
Following activation with dynabeads, retroviral trans-
duction and a 14 day period of cell culture, T cells were
sorted for either CD62L or CCR7 expression. Results
showed that, in comparison to CCR7 selection prior to
cell culture, CD62L selection at the end of cell culture
significantly increased the proportion of CD8+ (3.0 fold
P < 0.05) and CD4+ (1.32 fold P < 0.05) TEM populations,
however in both cases there was a trend of reduced
naïve cells. CCR7 selection post expansion led to a dras-
tic 2.3 fold increase (P < 0.001) in the population of CD8+
naive T cells up to 93.8% and simultaneous 67.7 fold de-
crease in TE proportion (P < 0.001) (Fig. 3c). In CD4
+ cells,
CCR7 selection did lead to a 1.9 fold increase in naïve sub-
sets (P < 0.05), but to a lower total of 26.3% whilst TCM
were increased in numbers 2.0 fold (P < 0.001), comple-
mentary decreases in TEM and TE were also observed
(Fig. 3d). Interestingly, CD62L nor CCR7 selection
following expansion in cell culture resulted in in-
creased proportion of the additional markers of early-
differentiation CD27 or CD62Lhi in CD4+ or CD8+
compartments compared to CCR7 selection prior to
expansion (Fig. 3e and f ).
CCR7+ selected cells display reduced exhaustion and
senescence
We assessed the expression of PD1, a marker of exhaus-
tion, after expansion of cells in vitro (Fig. 4a). Our first
observation was that about 10 fold more CD4+ cells than
CD8+ cells expressed PD1; 18.2% compared to 1.8%
respectively. Secondly, CD62L selection after 14 days ex-
pansion resulted in significantly higher levels of PD-1 ex-
pression compared to CCR7 selection in both CD8+ and
CD4+ subsets prior to (8.8 and 4.6 fold respectively), or
post expansion (25.4 and 11.7 fold respectively) (P < 0.001
in all cases). Interestingly, CD62L selection led to more
cells showing exhaustion than NSCs in both CD8+ (2.4
fold) and CD4+ (1.7 fold) subsets (P < 0.01 in both cases).
CCR7 selection either prior to, or post expansion yielded
a significant decrease in CD4+ cells expressing PD-1
compared to NSCs from 18.2 to 6.62% (P < 0.01) and
2.61% (P < 0.001) respectively.
In addition to PD1 as a marker of exhaustion, we ana-
lysed the expression of killer cell lectin-like receptor 1
(KLRG1) and CD127, a subunit of the IL-7 receptor; pre-
dicators of the replicative potential of T cells in vivo [39].
Based on expression of these markers we identified mem-
ory precursor effector cells (MPECs, KLRG1− CD127+),
double positive effector cells (DPECs, KLRG1+ CD127+),
short lived effector cells (SLECs, KLRG1+ CD127−) or
early effector cells (EECs, KLRG1−CD127−). MPECs have
large replicative potential and make up TEM and TCM
whilst SLECs and EECs are lost over time though
apoptosis. We observed about a 20% increase in num-
bers of MPECs upon CCR7 selection either prior to,
or post T cell expansion compared to NSCs in CD4+
(P < 0.01 and P < 0.001 respectively) and CD8+ cells
(P < 0.001 in both cases) (Fig. 4b and c). Notably,
there was no change in the yield of MPECs whether
cells were selected for CCR7 before or after expansion.
Conversely, compared to NSCs, CD4+ SLECs were signifi-
cantly reduced by CCR7 selection (P < 0.05) and CD8+
EECs were decreased by CCR7 selection prior to expan-
sion (P < 0.01). Consistent with observed increased PD-1
expression, CD62L selection did not increase the yield of
MPECs nor decrease the yield of SLECs or EECs com-
pared to NSCs in both CD4+ and CD8+ populations
(Fig. 4b and c).
Functionality of CCR7+ selected cells
CCR7 selection yields T cells of early-differentiation sta-
tus with potential for long-term persistence in vivo. Effi-
cacy of CAR T cell therapy, however, is also dependent
upon effector function of CAR T cells. We therefore
assessed the cytokine production and cytotoxicity of se-
lected T cells.
(See figure on previous page.)
Fig. 2 Proliferation kinetics and phenotype following various mitogenic stimuli. a Representative flow cytometry data 72 h following CFSE
staining and activation of T cells with mitogenic agents after selection for expression of CCR7. b Long term proliferation of T cells following
selection for expression of CCR7, mitogenic activation, transduction with RetroDMF5 and culture in IL-2. Expansion of NSC, CCR7+ and CCR7− T
cell populations was assessed after 14 days through enumeration of live cells. c The phenotype CD8+ T cell populations following CCR7 selection
and d Analysis of additional markers of early differentiation CD27, CD28 and CD62Lhi. Error bars show ± SEM. For phenotypes, significant difference
from plate bound antibody is shown
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Fig. 3 Effect of CD62L selection and timing of CCR7 selection on T cell phenotype. a CD8+ and b CD4+ T cell phenotypes following CD62L
selection. Significant difference from NSC T cells is shown. c CD8+ and d CD4+ T cell phenotypes following CCR7 selection prior to, or CD62L or
CCR7 selection post 14 days expansion ex vivo. Significant difference from CCR7 prior to expansion is shown. e CD8+ and f CD4+ T cell expression of
additional early differentiation markers following selection prior to, or post expansion ex vivo. Error bars show ± SEM
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As the DMF5 TCR is specific for an epitope of MART-1
when presented on HLA-A2, cytokine production of se-
lected T cells upon encountering target antigen was ana-
lysed by measuring production of IFNγ, IL-2, IL-10, IL-
17A and TNFα upon 16 h incubations with the MART-1+,
HLA-A2+ melanoma cell line, Mel-624. Equivalent num-
bers of RetroDMF5 transduced T cells that were either
non-sorted, CCR7 selected prior to in vitro expansion,
CCR7 selected post expansion or CD62L selected post
expansion were incubated with target Mel-624 cells. Using
SPICE application software [40], the multifunctionality of
T cells was characterised by the number of measured
cytokines produced. We observed little variation in
multifunctionality of NSC, CCR7 or CD62L selected,
RetroDMF5 transduced T cells. Although CCR7 selection
post expansion seemed to yield a slightly increased pro-
portion of cells secreting no cytokines after co-culture
with target Mel-624 cells (Fig. 5a).
It has been shown that IL-2 production is required for
the generation of CD8+ memory T cells with the ability to
mount secondary responses [41]. After incubation of
DMF5 transduced T cells with target Mel264 cells we iden-
tified IL-2 producing CD8+ T cells and further analysed
them based on their production of TNFα, IFNγ, IL-10 and
IL-17A via flow cytometry, however, neither IL-10 nor IL-
17A were co-produced with IL-2. FLOCK (FLOw Cytome-
try without K) analysis (http://www.immport.org/immport-
open/public/home/flowAnalysis) provides an algorithm to
functionally characterise cells based on several surface
markers without the bias of manual gating. FLOCK was
used to identify functional subpopulations of IL-2 produ-
cing CD8+ T cells based on high, intermediate, or low
levels of TNFα and IFNγ production. Results showed a
clear association of IL-2 production with TNFαlo, IFNγlo
and TNFαlo, IFNγint producing T cells upon incubation
with target melanoma cells (Fig. 5b and c). In addition,
CD62L selection post expansion gave rise to over a 3 fold
increase in numbers of TNFαlo, IFNγlo, IL-2 producing
cells than NSC or CCR7 selected cells both pre and post
expansion (P < 0.001 in all cases) and over a two fold in-
crease in numbers of TNFαlo, IFNγint, IL-2 producing cells
than NSC or CCR7 selected cells both pre and post expan-
sion (P < 0.001, P < 0.001 and P < 0.01 respectively). Of
note, CCR7 selection post expansion led to a 40% reduc-
tion in the proportion TNFαlo, IFNγint, IL-2 producing
cells compared to NSCs (P < 0.05).
As well as cytokine release, direct cytotoxicity of T cells
was assessed by measuring levels of CD107a, a marker of
degranulation and therefore direct cytotoxicity, upon
incubation of T cells with target melanoma cells. In order
to confirm MART1-HLA-A2 specific activation of
RetroDMF5 transduced T cells, Mel-888 cells that express
MART-1 and HLA-A1 were used as a control to quantify
any non-specific activation. Firstly, it was apparent that
there was little non-specific activation of CD8+ T cells by
Mel-888 cells (Fig. 5d). Secondly, we observed a high level
non-specific activation of CD4+ T cells (Fig. 5e); this could
be an experimental artefact or perhaps reflective of recent
work suggesting CD4+ T cell degranulation is less tightly
regulated than that of CD8+ counterparts [42].
Fig. 4 Exhaustion and senescence following T cell selection. a PD1 expression of CD8+ and CD4+ T cells following selection prior to, or post
14 days expansion ex vivo. Statistical analysis was performed using two separate one-way ANOVAS. b CD8+ and c CD4+ T cell subpopulations of
memory precursor effector cells (MPECs) KLRG1− CD127+, double positive effector cells (DPECs) KLRG1+ CD127+, short lived effector cells (SLECs)
KLRG1+ CD127− or early effector cells (EECs) KLRG1−CD127− following selection prior to, or post 14 days expansion ex vivo. Error bars show ± SEM
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Fig. 5 (See legend on next page.)
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CCR7 selection of T cells post expansion led to reduced
cytotoxicity compared to NSC (3.1 fold, P < 0.001), CCR7
selection prior to expansion (1.6 fold, P < 0.05) and
CD62L post expansion (3.6 fold, P < 0.001) to levels simi-
lar to background (Fig. 5d). CCR7 selection prior to ex-
pansion also led to a reduction in cytotoxicity compared
to NSCs (1.9 fold, P < 0.05) and CD62L selection post ex-
pansion (2.2 fold, P < 0.05) (Fig. 5d).
Together, these data suggest CCR7 cells have lower
short-term direct cytotoxicity to target tumour cells,
which we and others propose is indicative of an early-
differentiated phenotype and increased capacity of long
term engraftment in vivo, a trait required for tumour
eradication.
CCR7 selected human T cells exhibit enhanced
engraftment in vivo
Given that data suggests CCR7 selected T cells display mul-
tiple characteristic characteristics of early-differentiation
status we tested whether this led to enhanced engraftment
and reduction in tumour growth in the severely immuno-
deficient NSG (NOD/SCID IL-2Rγ-/-) mouse strain.
The NSG mouse model required to study the long
term effects of human T cells in mice is hampered by
the transferred T cells reacting to mouse antigens. The
immune reaction increases in intensity over time until at
around 50 days post T cell transfer when mice must be
sacrificed due to xenogenic graft versus host disease
[43–46]. This effect limits the time scale of tumour
eradication studies for CCR7 sorted T cells. Despite this
we analysed whether CCR7+ had more anti-tumour po-
tency than CCR7- magnetically sorted DMF5 TCR trans-
duced T cells over the course of 3 weeks in NSG
subcutaneously inoculated with Mel624 tumours. Al-
though there was a trend of a 2 fold reduction in tumour
volume after 3 weeks, results were not statistically sig-
nificant by two-way ANOVA (Additional file 2B).
To study the engraftment of adoptively transferred T
cells. Following transduction of with the RetroDMF5
TCR a dose of 2 × 107 non-sorted T cells or varying
doses of equivalent CCR7 selected cells were adminis-
tered to mice via intravenous (IV) injections. Blood sam-
ples collected by tail bleeds were analysed by flow
cytometry both 1 and 3 weeks following IV injections.
Upon analysis of the numbers of adoptively transferred
human CD4+ T cells in the circulation after 1 week the
numbers of human CD4+ T cells were 5.10 fold higher
(P < 0.01) in mice that received 2 × 107 CCR7 selected
cells than mice that received an equivalent dose of
NSCs. There was also no significant difference in num-
bers of circulating human CD4+ numbers in mice receiv-
ing 2 × 107 NSCs and 2 fold or 4 fold lower initial doses
of CCR7 selected cells (Fig. 6a). After 3 weeks it was ob-
served that CCR7 selection led to an 83.6 fold increase
(P < 0.01) in circulating CD4+ cells compared to NSCs at
an equivalent dose of 2 × 107 cells and a non-statistically
significant rise in mice receiving both 2 fold and 4 fold
lower doses of CCR7 selected cells (Fig. 6c).
Analysis of circulating human CD8+ T cells 1 week
after adoptive transfer showed there was no significant
increase in numbers in mice receiving 2 × 107 NSCs
compared those receiving an equivalent dose of CCR7
selected cells. In fact there was a significant decrease in
numbers of circulating CD8+ T cell numbers in mice re-
ceiving or 1 × 107 (6.81 fold, P < 0.001) or 5 × 106 (3.78
fold, P < 0.01) CCR7 selected cells compared to those re-
ceiving 2 × 107 NSCs. This reflects reduced input doses
and perhaps an intrinsically different efficiency of en-
graftment or proliferation of RetroDMF5 transduced
CD8+ T cells compared to CD4+ T cells. After 3 weeks,
however, we observed a 137 fold increase (P < 0.01) in
circulating human CD8+ T cell numbers in mice that re-
ceived 2 × 107 CCR7 selected cells than those that re-
ceived an equivalent dose of NSCs. Similar to the CD4+
circulating cells, a non-statistically significant increase in
numbers were also observed in mice that received both
2 and 4 fold lower doses of CCR7 selected cells than
those that received 2 × 107 NSCs.
Discussion
We demonstrate here that a bead based selection of
CCR7 expressing cells efficiently selects for T cells of
early differentiation status, significantly enhancing the
proportion of naïve cells whilst decreasing the preva-
lence of TEM and TE cells. This method has a slight bias
for CD4+ T cells, probably reflecting the proportion of
circulating cells in vivo. Despite a CD4+ bias, there was
no increase in CD4+ CD25+ CD27− FoxP3+ Tregs, which
may have a negative effect on anti-cancer potency of
adoptively transferred T cells.
Upon comparison of a range of mitogenic agents operat-
ing through αCD3 and αCD28 antibodies, we identified
(See figure on previous page.)
Fig. 5 Functionality of selected T cells. a Representative pie charts of T cell proportions secreting 0 – grey, 1 – blue, 2 – green, 3 – yellow or 4 – red
cytokines of a panel consisting of IFNγ, IL-2, IL-10, IL-17A and TNFα upon 16 h incubation with Mel-624 cells. b Visual representation and
c quantification of IL-2 secreting cell subsets following CCR7 selection prior to, or CD62L or CCR7 selection post expansion ex vivo and
incubation with target Mel-624 cells. Manual gating was utilised to identify CD8+ T cells and data from 4 biological repeats were pooled
before FLOCK analysis. d CD8+ and e CD4+ T cell CD107a expression following selection prior to, or post expansion and incubation with
target Mel-624 cells. Error bars show ± SEM
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dynabeads as an ideal agent for induction of both short
and long term proliferation of CCR7 sorted T cells whilst
inducing the least differentiation over a 2 week period.
This was evidenced by increased levels of CD27 and
CD62Lhi expressing cells and reduced TE numbers. These
observations are supported by data published elsewhere
but encompass a more complete panel of available mito-
genic agents, specifically with relation to gene modified T
cells enriched for early-differentiation status [47, 48].
In addition to CCR7, we attempted to enrich for cells
of early-differentiation status by utilising CD62Lhi, an-
other marker of early-differentiation. This did not prove
efficacious, perhaps due the presence of lower levels of
CD62L being present on more differentiated cells.
We assessed functional characteristics of Tcells postulated
to correlate with in vivo persistence. CCR7 selection either
prior to, or post T cell expansion led to cells with reduced
PD1 expression, indicating decreased levels of exhaustion, as
well as increased markers associated with high proliferative
capacity. In combination with phenotypic markers of early-
differentiation, this indicates that CCR7 selected cells have
increased capacity for persistence patients in vivo.
Upon incubation of CCR7 sorted, gene modified T
cells with target melanoma cells, multifunctionality was
largely unchanged compared to non-sorted T cells. Ana-
lysis of IL-2 producing CD8+ T cells following incuba-
tion with target Mel624 cells showed an increase in
TNFαlo, IFNγlo and TNFαlo, IFNγint IL-2 secreting popu-
lations in CD62L sorted cells. In all cases the number of
TNFα and IFNγ producing IL-2 secreting CD8 T cells
was lower in CCR7 sorted groups. As these have syner-
gistic effects on T cell proliferation this may be reflective
of a less effector and early differentiated phenotype, con-
comitant with other data presented here [49].
Importantly, CCR7 selection either prior to, or post
expansion led to a decrease in cytotoxicity of TCR-
transduced T cells upon incubation with target melan-
oma cells. This signifies early differentiation status and,
paradoxically, implies potential for higher anti-cancer ef-
ficacy in vivo, owing to increased capacity for long term
persistence.
Analysis of the persistence of human gene modified T
cells in mouse models are severely hampered by x-
GvHD therefore it is not possible to analyse human T
Fig. 6 Persistence of selected T cells in in vivo models. NSG mice were injected intravenously with CCR7 sorted or Non Sorted T cells and
analysed for circulating levels of adoptively transferred and T cells on days 7 a and b and 21 c and d; CD4+ and CD8+ respectively.
Error bars show ± SEM
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cells in mice in the long term [44]. However, it is pos-
sible to analyse engraftment levels of human T cells in
severely immunodefecient NSG mice before such xenor-
eactivity develops. Using this model we showed a drastic
increase in the numbers of adoptively transferred cells in
mice receiving CCR7 sorted cells over standard, non-
sorted cells. Upon comparison with CD62L sorted T
cells, which were of a more differentiated phenotype in
vitro, engraftment levels were similar after 3 weeks. We
hypothesised that over an extended period CCR7 sorted
cells would outperform CD62L sorted cells, however,
this was not evaluable in the NSG mouse model due to
the necessity to sacrifice mice after 4–6 weeks as a result
of x-GvHD.
We suggest that in order to validate the effects of
CCR7 selection on persistence of human cells in vivo,
clinical investigation must take place.
Conclusion
Sufficient levels of persistence of adoptively transferred T
cells are key for successful clinical outcomes. There is also
growing evidence that the proliferative capacity of T cells
is a principle determinant for efficient engraftment and
tumour clearance. It is, therefore, paramount, to deter-
mine optimal conditions for the production of T cells with
maximum proliferative potential on a clinical scale. This
study provides evidence that bead based selection of
CCR7+ T cells prior to adoptive cell therapy may provide a
means to enhance engraftment levels and may therefore
improve clinical success in multiple applications.
Additional files
Additional file 1: CD8 cell frequency and additional markers of
differentiation. A) CD8+ frequency following CCR7 selection of T-cells
following isolation. B) CD8+ and C) CD4+ T-cell expression of early
differentiation markers following CCR7 selection upon isolation. Error bars
show SEM. Statistical analysis was performed using one-way or two-way
ANOVA with Bonferroni’s post-tests. (TIF 17637 kb)
Additional file 2: Transduction levels and inhibition of Mel624 tumour
growth in NSG mice. A) RetroDMF5 transduction efficiency of CCR7
selected T-cells following activation with various mitogenic agents. Error
bars show SEM. Statistical analysis was performed using one-way ANOVA
with Bonferroni’s post-test. B) T cells were transduced with the DMF5 TCR
and magnetically sorted into CCR7+ and CCR7- fractions. These cells were
transferred to NSG mice with palpable, subcutaneous Mel624 tumours.
Tumour growth was assessed over the course of 3 weeks. Error bars
show + SEM. Statistical analysis was performed using two-way ANOVA.
(TIF 15008 kb)
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